Altimmune (ALT) Depreciation & Amortization - Total (2012 - 2017)
Altimmune (ALT) reported Depreciation & Amortization - Total of $33007.0 for Q1 2017, down 12.45% year-over-year from $37701.0 in Q1 2016, and little changed on a QoQ basis from $33066.0 in Q4 2016.
Altimmune (ALT) has 6 years of Depreciation & Amortization - Total data on file, last reported at $33007.0 in Q1 2017.
- Quarterly Depreciation & Amortization - Total fell 12.45% year-over-year to $33007.0 in Q1 2017, while the trailing twelve-month figure through Dec 2017 was $33007.0 (down 76.99% YoY) and the FY2016 annual result came in at $143437.0, up 1.29% from the prior year.
- Depreciation & Amortization - Total steadied at $33007.0 in Q1 2017 per ALT's latest filing, from $33066.0 in the prior quarter.
- Across five years, Depreciation & Amortization - Total topped out at $52602.0 in Q1 2013 and bottomed at $32235.0 in Q3 2016.
- The 5-year median for Depreciation & Amortization - Total is $37106.0 (2015), against an average of $38264.3.
- The widest annual swing landed in 2013, when Depreciation & Amortization - Total plunged 38.45%; it then advanced 10.22% in 2016.
- Tracing ALT's Depreciation & Amortization - Total over 5 years: stood at $43438.0 in 2013, then declined by 15.54% to $36686.0 in 2014, then slipped by 10.58% to $32806.0 in 2015, then increased by 0.79% to $33066.0 in 2016, then dropped by 0.18% to $33007.0 in 2017.
- Per Business Quant, the three latest ALT Depreciation & Amortization - Total figures stand at $33007.0 (Q1 2017), $33066.0 (Q4 2016), and $32235.0 (Q3 2016).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 33,007.00 |
| Dec 31, 2016 | 33,066.00 |
| Sep 30, 2016 | 32,235.00 |
| Jun 30, 2016 | 40,435.00 |
| Mar 31, 2016 | 37,701.00 |
| Dec 31, 2015 | 32,806.00 |
| Sep 30, 2015 | 35,005.00 |
| Jun 30, 2015 | 36,687.00 |
| Mar 31, 2015 | 37,106.00 |
| Dec 31, 2014 | 36,686.00 |
| Sep 30, 2014 | 37,125.00 |
| Jun 30, 2014 | 36,208.00 |
| Mar 31, 2014 | 39,939.00 |
| Dec 31, 2013 | 43,438.00 |
| Sep 30, 2013 | 44,593.00 |
| Jun 30, 2013 | 41,854.00 |
| Mar 31, 2013 | 52,602.00 |
| Dec 31, 2012 | 69,105.00 |
| Sep 30, 2012 | 72,453.00 |